[
  {
    "id": "c-001",
    "claim": "Azelastine is a fast-acting intranasal H1-receptor antihistamine that blocks histamine — a chemical released during allergic reactions — to relieve sneezing, itchy nose, runny nose, and nasal congestion",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/17723160/",
    "source_type": "PubMed"
  },
  {
    "id": "c-002",
    "claim": "Triamcinolone is an intranasal corticosteroid that reduces nasal inflammation by suppressing the production of inflammatory mediators (cytokines, prostaglandins, leukotrienes) involved in allergic rhinitis. With consistent daily use it gradually controls the inflammation that drives congestion and other nasal symptoms",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544309/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-003",
    "claim": "Ipratropium is an anticholinergic that blocks muscarinic receptors in the nasal lining to reduce glandular secretions, helping with runny nose. As a nasal spray, it acts locally in the nasal passages",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-004",
    "claim": "In short-term randomized trials (up to 4 weeks), co-administering an intranasal corticosteroid with oxymetazoline has not produced rhinitis medicamentosa, and intranasal corticosteroids reverse oxymetazoline-induced tachyphylaxis once it develops; long-term safety beyond a few weeks has not been established in large randomized trials",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/21377716/",
    "source_type": "PubMed"
  },
  {
    "id": "c-005",
    "claim": "Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-006",
    "claim": "For nasal symptoms of allergic rhinitis, intranasal antihistamines such as azelastine act locally on the nasal lining and have a rapid onset; clinical trials show benefit comparable to oral second-generation antihistamines, with particular advantage in patients not adequately controlled on oral therapy",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/17723160/",
    "source_type": "PubMed"
  },
  {
    "id": "c-007",
    "claim": "In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
    "source_type": "PubMed"
  },
  {
    "id": "c-008",
    "claim": "Saline nasal irrigation, used alongside standard medications, has been shown in a systematic review and meta-analysis (Hermelingmeier 2012) to modestly improve nasal symptom scores and reduce medication use in adults and children with allergic rhinitis",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/23168142/",
    "source_type": "PubMed"
  },
  {
    "id": "c-009",
    "claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
    "source_url": "https://www.allermi.com/pages/eligibility",
    "source_type": "allermi-library"
  },
  {
    "id": "c-010",
    "claim": "Allermi is currently available to eligible patients ages 13 and older across most US states",
    "source_url": "https://www.allermi.com/pages/eligibility",
    "source_type": "allermi-library"
  },
  {
    "id": "c-011",
    "claim": "Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections",
    "source_url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
    "source_type": "FDA"
  },
  {
    "id": "c-012",
    "claim": "Allergic rhinitis is a chronic condition with no pharmacologic cure; current guidelines focus on long-term symptom control and, where appropriate, allergen immunotherapy. Allermi is designed for daily use to manage symptoms over time",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-013",
    "claim": "Allermi treats allergic and non-allergic rhinitis — inflammation of the nasal lining; allergic rhinitis is sometimes called hay fever",
    "source_url": "https://www.allermi.com/pages/our-approach",
    "source_type": "allermi-library"
  },
  {
    "id": "c-014",
    "claim": "Allermi's intranasal corticosteroid component has very low systemic bioavailability when delivered through the nasal mucosa. Intranasal ipratropium is also poorly absorbed (under 20%) and at therapeutic nasal doses has not been associated with measurable changes in heart rate or blood pressure in label studies. Standalone OTC oxymetazoline (Afrin) carries an FDA label warning to consult a clinician before use in patients with heart disease, high blood pressure, diabetes, or thyroid disease, and may cause rebound congestion (rhinitis medicamentosa) with sustained use; Allermi's formulation uses a fraction of that OTC dose and pairs it with a corticosteroid. Patients with hypertension or any cardiovascular condition should review Allermi with their prescribing allergist and their cardiovascular clinician before starting or continuing therapy",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/15114430/",
    "source_type": "PubMed"
  },
  {
    "id": "c-015",
    "claim": "Although intranasal corticosteroids do not appear to increase the population-level incidence of glaucoma, they have been associated with small mean increases in intraocular pressure, which can matter for patients with pre-existing glaucoma. Patients with glaucoma should obtain clearance from their ophthalmologist before starting Allermi",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/35669010/",
    "source_type": "PubMed"
  },
  {
    "id": "c-016",
    "claim": "Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
    "source_type": "FDA-label"
  },
  {
    "id": "c-017",
    "claim": "The FDA approved Flonase Allergy Relief (fluticasone propionate 50 mcg) for over-the-counter sale in July 2014",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205434Orig1s000ltr.pdf",
    "source_type": "FDA"
  },
  {
    "id": "c-018",
    "claim": "Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-019",
    "claim": "Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
    "source_type": "FDA-label"
  },
  {
    "id": "c-020",
    "claim": "Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
    "source_type": "FDA-label"
  },
  {
    "id": "c-021",
    "claim": "In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/20203244/",
    "source_type": "PubMed"
  },
  {
    "id": "c-022",
    "claim": "Rhinitis medicamentosa is caused by prolonged use of topical nasal decongestant sprays — primarily the alpha-adrenergic vasoconstrictors such as oxymetazoline (Afrin), xylometazoline, naphazoline, and phenylephrine. The FDA label for OTC decongestant sprays advises against use beyond 3 days; case-series literature most often describes onset after about 5–7 days of continuous use, with onset varying widely",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/15725047/",
    "source_type": "PubMed"
  },
  {
    "id": "c-023",
    "claim": "Intranasal corticosteroids and intranasal antihistamines (e.g., azelastine, olopatadine) do not cause rhinitis medicamentosa. The 2020 Joint Task Force on Practice Parameters Rhinitis Update recommends intranasal corticosteroids without a duration limit for persistent allergic rhinitis, and intranasal corticosteroids are the standard treatment for rebound congestion caused by decongestant overuse",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-024",
    "claim": "In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child's clinician",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/25624374/",
    "source_type": "PubMed"
  },
  {
    "id": "c-025",
    "claim": "Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician",
    "source_url": "https://mothertobaby.org/fact-sheets/inhaled-corticosteroids-icss-pregnancy/",
    "source_type": "MotherToBaby"
  },
  {
    "id": "c-026",
    "claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
    "source_type": "PubMed"
  },
  {
    "id": "c-027",
    "claim": "Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-028",
    "claim": "It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-029",
    "claim": "Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bff57a5-cce0-401c-a0fe-23c65c1b7ddc",
    "source_type": "FDA-label"
  },
  {
    "id": "c-030",
    "claim": "Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-031",
    "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-032",
    "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
    "source_type": "FDA-label"
  },
  {
    "id": "c-033",
    "claim": "Flonase Sensimist (fluticasone furoate 27.5 mcg/spray) is FDA-labeled for OTC use in adults and children 2 years of age and older; the eye-symptom indication on the label is restricted to ages 12 and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=107100af-7ca2-44e8-b067-c0ab0a19a6dc",
    "source_type": "FDA-label"
  },
  {
    "id": "c-034",
    "claim": "Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffca32a2-fbef-40bb-b0f0-73f63e18e747",
    "source_type": "FDA-label"
  },
  {
    "id": "c-035",
    "claim": "In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213872Orig1s000Lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-036",
    "claim": "In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/19930788/",
    "source_type": "PubMed"
  },
  {
    "id": "c-037",
    "claim": "Bitter taste is the most commonly reported side effect of azelastine nasal sprays, occurring in roughly 6–10% of patients in placebo-controlled trials of Astepro 0.15% versus 1–2% on placebo. It typically occurs when spray drains into the throat and can be reduced by tilting the head downward during use",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022203s006lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-038",
    "claim": "In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022203s006lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-039",
    "claim": "Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c557ec4-c4cf-11df-851a-0800200c9a66",
    "source_type": "FDA-label"
  },
  {
    "id": "c-040",
    "claim": "In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
    "source_type": "PubMed"
  },
  {
    "id": "c-041",
    "claim": "Ipratropium nasal spray is a topical anticholinergic (muscarinic-receptor antagonist) that reduces nasal mucous secretion (rhinorrhea); per the FDA Atrovent 0.03% prescribing information it does not relieve nasal congestion, sneezing, or post-nasal drip",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-042",
    "claim": "Intranasal ipratropium acts locally on the nasal mucosa to reduce watery rhinorrhea; it is not used as a bronchodilator. Ipratropium's bronchodilator effect requires the inhaled aerosol or nebulized formulations, which are FDA-approved for COPD and used adjunctively in acute asthma",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-043",
    "claim": "Ipratropium nasal spray reduces watery rhinorrhea in nonallergic rhinitis (sometimes called vasomotor rhinitis — cold-air, irritant, or food-triggered runny nose), with randomized trials in perennial nonallergic rhinitis showing roughly a 30% reduction in rhinorrhea versus saline placebo",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/7751528/",
    "source_type": "PubMed"
  },
  {
    "id": "c-044",
    "claim": "Cromolyn sodium (NasalCrom) is a mast-cell stabilizer that blocks histamine and other mediator release. Because it is poorly absorbed systemically, it is well tolerated and has an excellent overall safety record",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/11936930/",
    "source_type": "PubMed"
  },
  {
    "id": "c-045",
    "claim": "Intranasal cromolyn sodium is generally less potent than intranasal corticosteroids for moderate-to-severe allergic rhinitis and requires more frequent dosing (typically 3 to 4 times daily). Allergy practice guidelines therefore reserve it for milder symptoms or for patients who prefer to avoid corticosteroids",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-046",
    "claim": "The FDA label for Afrin Original (oxymetazoline hydrochloride 0.05% nasal spray) instructs consumers to not use the product for more than 3 days, warning that frequent or prolonged use may cause nasal congestion to recur or worsen",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89c165ba-3ad5-49b5-a5bb-423dc8e15bad",
    "source_type": "FDA-label"
  },
  {
    "id": "c-047",
    "claim": "Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-048",
    "claim": "Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
    "source_type": "PubMed"
  },
  {
    "id": "c-049",
    "claim": "In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/35712651/",
    "source_type": "PubMed"
  },
  {
    "id": "c-050",
    "claim": "In one small randomized controlled trial (Watanabe 2003, n=30 healthy adults), oxymetazoline nasal spray three times daily for four weeks did not produce rebound congestion or tachyphylaxis versus placebo. Most decongestant labels still recommend limiting use to 3 days, and rebound is well documented in patients with chronic rhinitis",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/14579657/",
    "source_type": "PubMed"
  },
  {
    "id": "c-051",
    "claim": "First-trimester exposure to specific intranasal decongestants, including oxymetazoline, has been linked in hypothesis-generating analyses of the Slone Epidemiology Center Birth Defects Study (Yau 2013) to small increases in the risk of certain rare birth defects; the strongest replicated signals were for oral phenylephrine and oral phenylpropanolamine, with weaker hypothesis-generating signals for intranasal oxymetazoline",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/23825167/",
    "source_type": "PubMed"
  },
  {
    "id": "c-052",
    "claim": "Case-control epidemiology has linked first-trimester oral pseudoephedrine to small increased risks of gastroschisis (Werler 2002, OR ~1.8; 95% CI 1.0–3.2) and small-intestinal atresia (OR ~2.0; 95% CI 1.0–4.0), with the signal stronger when pseudoephedrine is combined with acetaminophen. ACOG recommends avoiding pseudoephedrine in the first trimester",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/11772781/",
    "source_type": "PubMed"
  },
  {
    "id": "c-053",
    "claim": "Pregnancy rhinitis affects roughly one in five pregnant patients (about 20%), is thought to be driven by hormonal changes, and by definition resolves completely within about two weeks after delivery",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/15208461/",
    "source_type": "PubMed"
  },
  {
    "id": "c-054",
    "claim": "Because saline nasal sprays and saline irrigation contain no active drug, they are widely recommended as a first-line, drug-free option for nasal symptoms during pregnancy. Consensus guidelines specifically endorse saline irrigation for rhinitis of pregnancy (Rabago 2009)",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/19904896/",
    "source_type": "PubMed"
  },
  {
    "id": "c-055",
    "claim": "A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/10074986/",
    "source_type": "PubMed"
  },
  {
    "id": "c-056",
    "claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
    "source_type": "PubMed"
  },
  {
    "id": "c-057",
    "claim": "Human pregnancy data for intranasal azelastine are limited; animal studies have not shown teratogenicity, but published human studies are sparse. Many OB/GYNs prefer intranasal corticosteroids such as budesonide for pregnant patients, where pregnancy-specific data are more robust",
    "source_url": "https://mothertobaby.org/fact-sheets/azelastine/",
    "source_type": "MotherToBaby"
  },
  {
    "id": "c-058",
    "claim": "Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501215/",
    "source_type": "LactMed"
  },
  {
    "id": "c-059",
    "claim": "Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK500777/",
    "source_type": "LactMed"
  },
  {
    "id": "c-060",
    "claim": "Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501039/",
    "source_type": "LactMed"
  },
  {
    "id": "c-061",
    "claim": "Per LactMed, occasional small doses of intranasal azelastine are not expected to affect a breastfed infant, but larger or prolonged doses may cause infant drowsiness or reduce milk supply; oral nonsedating antihistamines are LactMed's preferred alternative during breastfeeding",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501061/",
    "source_type": "LactMed"
  },
  {
    "id": "c-062",
    "claim": "Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/24228841/",
    "source_type": "PubMed"
  },
  {
    "id": "c-063",
    "claim": "Rhinitis medicamentosa typically resolves over days to a few weeks after stopping the offending decongestant. Adding an intranasal corticosteroid can accelerate symptom recovery, with subjective rebound congestion improving within 48 hours in some cases and objective mucosal recovery often taking 1–2 weeks",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK538318/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-064",
    "claim": "The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
    "source_type": "guideline"
  },
  {
    "id": "c-065",
    "claim": "Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/14726906/",
    "source_type": "PubMed"
  },
  {
    "id": "c-066",
    "claim": "Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/12959630/",
    "source_type": "PubMed"
  },
  {
    "id": "c-067",
    "claim": "Allermi runs approximately $45 per month on a direct subscription, including allergist consultation, compounded prescription, and shipping",
    "source_url": null,
    "source_type": "editorial"
  },
  {
    "id": "c-068",
    "claim": "Allermi is generally not covered by commercial insurance and is paid out-of-pocket",
    "source_url": "https://www.allermi.com/blogs/learn/how-much-does-allermi-cost",
    "source_type": "allermi-library"
  },
  {
    "id": "c-069",
    "claim": "Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size",
    "source_url": "https://www.goodrx.com/fluticasone",
    "source_type": "GoodRx"
  },
  {
    "id": "c-070",
    "claim": "Intranasal cromolyn sodium has a long-standing favorable safety record and minimal systemic absorption (Ratner 2002); per LactMed, cromolyn is generally considered acceptable during pregnancy and lactation when symptoms warrant pharmacotherapy, especially as a non-steroid adjunct",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/11936930/",
    "source_type": "PubMed"
  },
  {
    "id": "c-071",
    "claim": "Intranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience",
    "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK542161/",
    "source_type": "StatPearls"
  },
  {
    "id": "c-072",
    "claim": "Common side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
    "source_type": "FDA-label"
  },
  {
    "id": "c-073",
    "claim": "For fast symptomatic relief, intranasal azelastine has a rapid 15-minute onset of action (Patel 2007), while intranasal corticosteroids like fluticasone may take several days to reach maximum effect, with full benefit typically over 1–2 weeks of regular use",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/17882923/",
    "source_type": "PubMed"
  },
  {
    "id": "c-074",
    "claim": "Allergic rhinitis with sneezing and itch responds to intranasal antihistamines and intranasal corticosteroids; in nonallergic / vasomotor rhinitis where rhinorrhea predominates, intranasal ipratropium has demonstrated meaningful reduction (about 30% over vehicle) in randomized trials",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/7751528/",
    "source_type": "PubMed"
  },
  {
    "id": "c-075",
    "claim": "Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/10227333/",
    "source_type": "PubMed"
  },
  {
    "id": "c-076",
    "claim": "In an environmental exposure chamber study (Patel 2007), intranasal azelastine produced statistically significant symptom relief 15 minutes after dosing, with a durable effect over 8 hours of continued ragweed-pollen exposure",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/17882923/",
    "source_type": "PubMed"
  },
  {
    "id": "c-077",
    "claim": "Flonase Allergy Relief (fluticasone propionate) contains phenylethyl alcohol, a floral-scented inactive ingredient that gives the spray a noticeable rose-like aroma. Nasacort, Flonase Sensimist, and Rhinocort do not contain phenylethyl alcohol or other fragrance compounds and are essentially scent-free",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
    "source_type": "FDA-label"
  },
  {
    "id": "c-078",
    "claim": "Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon",
    "source_url": "https://www.goodrx.com/dymista",
    "source_type": "GoodRx"
  },
  {
    "id": "c-079",
    "claim": "Allermi uses oxymetazoline at 0.003125–0.0125% in a 0.1 mL per-spray volume — roughly 1/4 to 1/16 the 0.05% concentration in OTC Afrin Original, and approximately 1/12 to 1/48 the per-spray oxymetazoline dose, per Allermi's published formulation specs",
    "source_url": "https://www.allermi.com/blogs/learn/what-s-the-deal-with-oxymetazoline",
    "source_type": "allermi-library"
  },
  {
    "id": "c-080",
    "claim": "Allermi is designed for sustained daily use, with a prescribing allergist reviewing your response and adjusting your formula as needed",
    "source_url": "https://www.allermi.com/pages/our-approach",
    "source_type": "allermi-library"
  },
  {
    "id": "c-081",
    "claim": "NasalCrom (cromolyn sodium) is dosed at 1 spray per nostril 3 to 4 times daily (every 4 to 6 hours), with up to 6 doses per day if needed; consistent daily use is required because the effect builds over 1 to 2 weeks",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b34d36ca-4df4-458c-af0f-c0d0c9a025d9",
    "source_type": "FDA-label"
  },
  {
    "id": "c-082",
    "claim": "Ipratropium nasal 0.03% is FDA-approved for runny nose from allergic and non-allergic perennial rhinitis (ages 6+). The 0.06% strength is approved for runny nose from the common cold (up to 4 days) or seasonal allergic rhinitis (up to 3 weeks) in patients 5 and older",
    "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13a45df5-a8e3-41d6-91f4-773255b5a04b",
    "source_type": "FDA-label"
  },
  {
    "id": "c-083",
    "claim": "In a 1-year randomized open-label safety study of Dymista (MP29-02) in 612 patients with chronic rhinitis (Berger 2014), treatment-related adverse events were low (9.4%) and comparable to fluticasone propionate alone, with no septal perforations and no clinically meaningful cortisol changes — supporting sustained daily use",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/24607046/",
    "source_type": "PubMed"
  },
  {
    "id": "c-084",
    "claim": "In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/25624374/",
    "source_type": "PubMed"
  },
  {
    "id": "c-085",
    "claim": "Mometasone furoate has greater glucocorticoid-receptor binding affinity than fluticasone propionate (Flonase) and triamcinolone acetonide (Nasacort), supporting its higher relative potency among the older OTC intranasal corticosteroids; fluticasone furoate (Flonase Sensimist) has comparable receptor affinity",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
    "source_type": "FDA-label"
  },
  {
    "id": "c-086",
    "claim": "Nasonex is the only OTC nasal spray with FDA approval for treatment of chronic rhinosinusitis with nasal polyps in adults 18 and older (per FDA prescribing information; Nasonex 24HR went OTC in 2022). Allergic-rhinitis indication remains ages 12 and older.",
    "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
    "source_type": "FDA-label"
  }
]